Literature DB >> 8216828

Adherence in combination with lipopolysaccharide, tumor necrosis factor or interleukin-1 beta potentiates the induction of monocyte-derived interleukin-8.

K Kasahara1, R M Strieter, T J Standiford, S L Kunkel.   

Abstract

In this study we demonstrate that adherence of peripheral blood mononuclear cells (PBMC) to either plastic or extracellular matrix, such as collagen type I or fibronectin, is a significant stimulus for the induction of both interleukin-8 (IL-8) mRNA and antigen. In addition, adherence of PBMC in the presence of lipopolysaccharide, interleukin-1-beta, or tumor necrosis factor-alpha greatly enhances transcription/translation of IL-8 from these leukocytes. Our findings demonstrate that PBMC adherent to either plastic or physiological surfaces in combination with an inflammatory agonist is both a potent and efficacious signal for the expression and production of the neutrophil chemotactic/activating cytokine, IL-8.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8216828     DOI: 10.1159/000163762

Source DB:  PubMed          Journal:  Pathobiology        ISSN: 1015-2008            Impact factor:   4.342


  3 in total

Review 1.  Discoidin domain receptor 1: a new class of receptor regulating leukocyte-collagen interaction.

Authors:  Teizo Yoshimura; Wataru Matsuyama; Hidenobu Kamohara
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

2.  Monocyte adherence to the subendothelial basement membrane increases interleukin-8 gene expression and antigen release.

Authors:  L A Heinel; D Singleton; M Miller; M B Frewin; P W Gudewicz
Journal:  Inflammation       Date:  1995-10       Impact factor: 4.092

3.  Persistently elevated level of IL-8 in Chlamydia trachomatis infected HeLa 229 cells is dependent on intracellular available iron.

Authors:  Harsh Vardhan; Raini Dutta; Vikas Vats; Rishein Gupta; Rajneesh Jha; Hem Chandra Jha; Pragya Srivastava; Apurb Rashmi Bhengraj; Aruna Singh Mittal
Journal:  Mediators Inflamm       Date:  2009-05-26       Impact factor: 4.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.